仑伐替尼二线治疗复发性子宫内膜癌的2期研究
这项国际开放标签单臂多中心2期试验评估仑伐替尼二线治疗不可切除复发性子宫内膜癌的疗效,共133例患者入组,每日口服24 mg。独立影像学评估的客观缓解率为14.3%(95%CI 8.8-21.4),中位无进展生存期5.6个月、总生存期10.6个月,不良反应以乏力、高血压等为主,总体可耐受。
要点
- 仑伐替尼二线治疗的客观缓解率为14.3%,临床获益率37.6%。
- 中位无进展生存期5.6个月,中位总生存期10.6个月。
- 基线血管生成素-2水平较低与更长的无进展生存期、总生存期及更高客观缓解率相关。
核心结论
- 仑伐替尼二线治疗复发性子宫内膜癌显示出适度的抗肿瘤活性,且总体耐受性良好,安全性与既往研究一致。
研究设计与样本
- 国际、开放标签、单臂、多中心2期试验,共纳入133例经组织学确诊、既往接受过一种含铂全身化疗后复发的不可切除子宫内膜癌患者。
- 患者接受每日一次口服仑伐替尼24 mg,按28天为一个给药周期。
主要发现
- 经独立影像学评估,19例患者获得确认的客观缓解,客观缓解率为14.3%(95%CI 8.8-21.4)。
- 31例(23.3%)观察到持久稳定疾病(≥23周),临床获益率为37.6%(95%CI 29.3-46.4)。
- 中位无进展生存期为5.6个月(95%CI 3.7-6.3),中位总生存期为10.6个月(95%CI 8.9-14.9)。
- 任何级别最常见治疗相关不良事件包括乏力/虚弱(48%)、高血压(49%)、恶心/呕吐(32%)、食欲下降(32%)和腹泻(31%)。
- 基线血管生成素-2水平较低与更长的无进展生存期、总生存期及更高的客观缓解率相关。
关键数值与推荐
- 客观缓解率14.3%(95%CI 8.8-21.4),临床获益率37.6%(95%CI 29.3-46.4)。
- 中位无进展生存期5.6个月(95%CI 3.7-6.3),中位总生存期10.6个月(95%CI 8.9-14.9)。
- 仑伐替尼用法为每日一次口服24 mg,28天为一个给药周期。
临床怎么用
- 对于既往含铂化疗后复发的不可切除子宫内膜癌患者,仑伐替尼可作为二线治疗选择之一,但需权衡其适度疗效与乏力、高血压等不良反应。
局限性
- 本研究为单臂设计,缺乏随机对照,结论的因果推断受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study assessed the efficacy of lenvatinib, a multitargeted tyrosine kinase inhibitor, as second-line therapy in patients with unresectable endometrial cancer. The primary end point was the objective response rate (ORR) as assessed by independent radiologic review (IRR). Secondary end points included median progression-free survival (PFS), overall survival (OS), and clinical benefit rate. Exploratory end points examined the association of baseline levels of plasma biomarkers (50 circulating cytokine and/or angiogenic factors measured by immunoassays) with efficacy outcomes. METHODS: An international, open-label, single-arm, multicenter, phase 2 trial was conducted. Eligible patients had histologically confirmed unresectable endometrial cancer that relapsed after 1 prior systemic platinum-based chemotherapy. Patients received once-daily oral lenvatinib 24 mg in a 28-day dosing cycle. RESULTS: There were 133 patients in the study. By IRR, 19 patients had a confirmed objective response for an ORR of 14.3% (95% CI: 8.8-21.4). Durable stable disease (≥23 weeks) was observed in 31 patients (23.3%) and the clinical benefit rate was 37.6% (95% CI: 29.3-46.4). Median PFS was 5.6 months (95% CI: 3.7-6.3), and median OS was 10.6 months (95% CI: 8.9-14.9). The most common (any grade) treatment-related adverse events were fatigue/asthenia (48%), hypertension (49%), nausea/vomiting (32%), decreased appetite (32%), and diarrhea (31%). Lower baseline levels of angiopoietin-2 were associated with longer PFS, OS, and a higher ORR. CONCLUSIONS: Patients with recurrent endometrial cancer treated with second-line lenvatinib experienced modest antitumor activity and treatment was generally well tolerated, with a safety profile consistent with previous studies.
引用
- Vergote I, Powell MA, Teneriello MG, et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020. PMID: 31955859. doi:10.1016/j.ygyno.2019.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。